ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.
Article Links:
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study. (ESC heart failure)
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. (ESC heart failure)
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. (ESC heart failure)
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. (Hypertension (Dallas, Tex. : 1979))
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/
Featured Articles
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40963190
Summary: This analysis of the TOPCAT trial’s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958744
Summary: This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958495
Summary: Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959903
Summary: This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959886
Summary: Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.
Transcript
Today’s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Soluble urokinase plasminogen activator receptor and outcomes in Heart Failure with Preserved Ejection Fraction: A TOPCAT ancillary study. This analysis of the TOPCAT trial’s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.
Article number two. Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.
Article number three. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.
Article number four. PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.
Article number five. Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.
Thank you for listening. Don’t forget to subscribe.
Keywords
Mendelian randomization, DAPA-MI trial, hypertension, myeloperoxidase, blood pressure, cancer therapy-related cardiac dysfunction, biomarkers, cardiac inflammation, myocardial infarction, breast cancer, heart failure, left ventricular ejection fraction, pulmonary remodeling, Heart Failure with Preserved Ejection Fraction, mortality, cardiovascular mortality, soluble urokinase plasminogen activator receptor, dapagliflozin, cardiovascular death, prolyl hydroxylase domain protein 2, inflammation, CD8 positive T cells, TOPCAT trial, meta-analysis, cardiometabolic outcomes.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25 first appeared on Cardiology Today.
Article Links:
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study. (ESC heart failure)
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. (ESC heart failure)
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. (ESC heart failure)
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. (Hypertension (Dallas, Tex. : 1979))
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/
Featured Articles
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40963190
Summary: This analysis of the TOPCAT trial’s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958744
Summary: This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958495
Summary: Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959903
Summary: This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959886
Summary: Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.
Transcript
Today’s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Soluble urokinase plasminogen activator receptor and outcomes in Heart Failure with Preserved Ejection Fraction: A TOPCAT ancillary study. This analysis of the TOPCAT trial’s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.
Article number two. Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.
Article number three. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.
Article number four. PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.
Article number five. Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.
Thank you for listening. Don’t forget to subscribe.
Keywords
Mendelian randomization, DAPA-MI trial, hypertension, myeloperoxidase, blood pressure, cancer therapy-related cardiac dysfunction, biomarkers, cardiac inflammation, myocardial infarction, breast cancer, heart failure, left ventricular ejection fraction, pulmonary remodeling, Heart Failure with Preserved Ejection Fraction, mortality, cardiovascular mortality, soluble urokinase plasminogen activator receptor, dapagliflozin, cardiovascular death, prolyl hydroxylase domain protein 2, inflammation, CD8 positive T cells, TOPCAT trial, meta-analysis, cardiometabolic outcomes.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25 first appeared on Cardiology Today.
In God we trust